Opinion/decision on a Paediatric investigation plan (PIP): Agamree, vamorolone, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Congenital, familial and genetic disorders, PIP number: EMA/PE/0000244420

Submitted by Anonymous (not verified) on 9 October 2026 - 8:26

Opinion/decision on a Paediatric investigation plan (PIP): Agamree, vamorolone, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Congenital, familial and genetic disorders, PIP number: EMA/PE/0000244420

Opinion/decision on a Paediatric investigation plan (PIP): Emgality, Galcanezumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Surgical and medical procedures, PIP number: EMA/PE/0000227737

Submitted by Anonymous (not verified) on 9 October 2026 - 8:00

Opinion/decision on a Paediatric investigation plan (PIP): Emgality, Galcanezumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Surgical and medical procedures, PIP number: EMA/PE/0000227737

Opinion/decision on a Paediatric investigation plan (PIP): Aimovig, erenumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Surgical and medical procedures, PIP number: EMA/PE/0000242151

Submitted by Anonymous (not verified) on 9 October 2026 - 7:47

Opinion/decision on a Paediatric investigation plan (PIP): Aimovig, erenumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Surgical and medical procedures, PIP number: EMA/PE/0000242151

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness